Syndicate content The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
Updated: 33 min 8 sec ago

CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments

Tue, 01/06/2015 - 13:05
Financing will help support advancement of Probody therapeutics towards the clinic SOUTH SAN FRANCISCO, Calif., Jan. 6, 2015 -- (Healthcare Sales & Marketing Network) -- CytomX, a biotechnology company developing Probody™ therapeutics for the treatment...
Biopharmaceuticals, Oncology, Venture Capital
CytomX Therapeutics, Probody

Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics

Tue, 01/06/2015 - 13:00
Isis-owned Subsidiary Launched to Conduct Development and Commercialization of Isis' Lipid Franchise Drugs CARLSBAD, Calif. and CAMBRIDGE, Mass., Jan. 6, 2015 -- (Healthcare Sales & Marketing Network) -- Isis Pharmaceuticals, Inc. (ISIS) announced toda...
Biopharmaceuticals, Personnel
Isis Pharmaceuticals, Akcea Therapeutics

Cohera Medical, Inc.(R) Receives PMA Approvable Letter from U.S. FDA for TissuGlu(R) Surgical Adhesive

Tue, 01/06/2015 - 12:53
Cohera CEO to present on latest Company updates at 33rd Annual J.P. Morgan Healthcare Conference PITTSBURGH, Jan. 6, 2015 -- (Healthcare Sales & Marketing Network) -- Cohera Medical, Inc.®, a leading innovator and developer of absorbable surgical a...
Devices, FDA
Cohera Medical, surgical adhesive, TissuGlu

CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme (Brain Cancer)

Tue, 01/06/2015 - 12:46
Aldoxorubicin Shows a Complete Response, Tumor Shrinkage, Prolonged Stable Disease, and Favorable Tolerability in Patients Novel Albumin-Binding Drug Candidate Appears to Allow Doxorubicin to Cross the Tumor's Blood-Brain Barrier in Humans LOS ANGELE...
Biopharmaceuticals, Oncology
CytRx, aldoxorubicin, glioblastoma multiforme, brain cancer

Catalyst Pharmaceuticals Appoints David D. Muth, Executive Vice President, Chief Commercial Officer

Mon, 01/05/2015 - 23:56
CORAL GABLES, Fla., Jan. 5, 2015 -- (Healthcare Sales & Marketing Network) -- Catalyst Pharmaceutical Partners, Inc. (Catalyst Pharmaceuticals) (CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people wi...
Biopharmaceuticals, Personnel
Catalyst Pharmaceutical, Firdapse

GlySens Incorporated Secures $12M Series C Investment

Mon, 01/05/2015 - 23:51
Proceeds dedicated to advanced product commercialization steps SAN DIEGO, Jan. 5, 2015 -- (Healthcare Sales & Marketing Network) -- GlySens Incorporated announced today that it has closed a $12 million dollar Series C investment round, which included p...
Devices, Endocrinology, Venture Capital
GlySens, continuous glucose monitoring system

Aduro Biotech Closes $51.4 Million Series D Financing

Mon, 01/05/2015 - 13:12
Investment for Expansion of Research and Clinical Development of Aduro’s Immuno-Oncology Technology Platforms BERKELEY, Calif.--(Healthcare Sales & Marketing Network)--Aduro Biotech, Inc., a clinical-stage immuno-oncology company, today announced the cl...
Biopharmaceuticals, Oncology, Venture Capital
Aduro Biotech

Stereotaxis Receives FDA Clearance of Vdrive(R) With V-CAS(TM) System Along With Regulatory Approval of Odyssey(R) System in Japan

Mon, 01/05/2015 - 13:05
ST. LOUIS, Jan. 5, 2015 -- (Healthcare Sales & Marketing Network) -- Stereotaxis, Inc. (STXS) announced today that it has received 510(k) clearance by the Food and Drug Administration (FDA) for its Vdrive(R) with V-CAS(TM) Catheter Advancement System in th...
Devices, Cardiology, Regulatory
Stereotaxis, Vdrive , V-CAS , Catheter Advancement System

CardioFocus partners with Japan Lifeline for distribution of the HeartLight Laser Balloon to treat Atrial Fibrillation

Mon, 01/05/2015 - 12:58
Massachusetts company taps Japan EP market leader to introduce proprietary technology MARLBOROUGH, Mass., Jan. 5, 2015 -- (Healthcare Sales & Marketing Network) -- CardioFocus, Inc., developer of the HeartLight® Endoscopic Ablation System for the t...
Devices, Cardiology, Distribution
CardioFocus, Japan Lifeline Co, HeartLight, Endoscopic Ablation

Exact Sciences: Additional Update on CMS Reimbursement for Cologuard(R)

Fri, 01/02/2015 - 12:45
MADISON, Wis.--(Healthcare Sales & Marketing Network)--Exact Sciences Corp. (EXAS) today announced that the Centers for Medicare and Medicaid Services (CMS) has published an updated 2015 Clinical Laboratory Fee Schedule, which includes reimbursement for Ex...
Diagnostics, Reimbursement
Exact Sciences, Cologuard, colon cancer

Lightpoint Medical Raises £2 Million in Series A Funding Round

Tue, 12/30/2014 - 14:10
RICKMANSWORTH, England, December 30, 2014 -- (Healthcare Sales & Marketing Network) --Lightpoint Medical, a developer of innovative surgical imaging technologies, announced today that the company has raised £2 million ($3.1 million) in a Series A fi...
Devices, Venture Capital
Lightpoint Medical, LightPath, EnLight , Cerenkov Luminescence

BioTime Appoints Adi Mohanty Chief Operating Officer

Mon, 12/29/2014 - 13:45
Executive Brings Proven Leadership in Biopharmaceutical Product Development and Commercialization to BioTime ALAMEDA, Calif.--(Healthcare Sales & Marketing Network)--BioTime, Inc. (NYSE MKT:BTX), a leader in developing pluripotent stem-cell therapies an...
Regenerative Medicine, Personnel
BioTime

Jean Boulle Group Reports Successful First Clinical Trial Implant of the Tendyne Transcatheter Mitral Valve

Mon, 12/29/2014 - 13:26
LUXEMBOURG, December 29, 2014 -- (Healthcare Sales & Marketing Network) --Boulle Medtech Ltd, a Jean Boulle Group company focusing on medical technology and a founding investor of Tendyne Holdings, Inc. ("Tendyne"), is pleased to announce that t...
Devices, Interventional Cardiology
Jean Boulle Group, Boulle Medtech, Tendyne, Transcatheter Mitral Valve Implant

Roche receives FDA Emergency Use Authorization for the LightMix(R) Ebola Zaire rRT-PCR Test

Mon, 12/29/2014 - 13:14
PLEASANTON, Calif., Dec. 29, 2014 -- (Healthcare Sales & Marketing Network) -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has provided an Emergency Use Authorization (EUA) for the LightMix® Ebol...
Diagnostics
Roche, LightMix Ebola Zair, Ebola

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong